Physician profile
Anchi Wang
NPI 1093744542
$9,183.51
in general payments reported to CMS, 2019-2025
47 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,469 · 2020: $1,392 · 2021: $971 · 2022: $639 · 2023: $231 · 2024: $327 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711 · Education: $0.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.81 |
| Education | $0.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $1,828.21 | 2019-2023 | Gocovri |
| Sunovion Pharmaceuticals INC. | $1,052.53 | 2019-2022 | |
| Abbvie INC. | $941.06 | 2019-2025 | Botox, Ubrelvy, Qulipta |
| Amgen INC. | $488.69 | 2019-2025 | Uplizna |
| Allergan, INC. | $463.96 | 2019-2021 | |
| Boston Scientific Corporation | $337.12 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $328.38 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $325.63 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $319.30 | 2019-2023 | Austedo Xr |
| Acadia Pharmaceuticals INC | $277.84 | 2019-2021 | |
| Merz North America, INC. | $211.21 | 2019-2020 | |
| Kyowa Kirin, INC. | $205.98 | 2019-2020 | |
| Ucb, INC. | $196.02 | 2019-2020 | |
| Lilly USA, LLC | $185.55 | 2019-2022 | |
| Greenwich Biosciences, INC. | $177.42 | 2019 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anchi Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.